{
    "clinical_study": {
        "@rank": "109146", 
        "arm_group": {
            "arm_group_label": "Bacteriotherapy", 
            "arm_group_type": "Experimental", 
            "description": "Study stool recipient's will receive approximately 30 grams of processed donor stool through a tube into their stomach for the transplant."
        }, 
        "brief_summary": {
            "textblock": "In this study, the investigators want to see if Bacteriotherapy (also referred to as stool\n      transplantation) improves the symptoms and decreases inflammation in children with\n      Inflammatory Bowel Disease (IBD). Examples of IBD are Crohn's Disease and Ulcerative\n      Colitis. Additionally, researchers want to learn whether this experimental therapy delays\n      the need for starting additional medications to treat pediatric IBD."
        }, 
        "brief_title": "Bacteriotherapy in Pediatric Inflammatory Bowel Disease", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Inflammatory Bowel Disease", 
            "Crohn's Disease", 
            "Ulcerative Colitis", 
            "CD"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Crohn Disease", 
                "Inflammatory Bowel Diseases", 
                "Intestinal Diseases", 
                "Ulcer"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Children ages 12-21 years old with a diagnosis of mild to moderate Ulcerative Colitis\n             or Crohn's Disease\n\n          -  Willing parent to donate stool for the transplant\n\n        Exclusion Criteria:\n\n          -  Severe Disease\n\n          -  History of intra-abdominal abscess, intra-abdominal fistula or stricturing\n\n          -  History of other systemic diseases\n\n          -  The patient has received TNF inhibitors to treat their IBD within two months of\n             transplant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01757964", 
            "org_study_id": "14267"
        }, 
        "intervention": {
            "arm_group_label": "Bacteriotherapy", 
            "intervention_name": "Bacteriotherapy", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Crohns Disease", 
            "Ulcerative Colitis", 
            "Inflammatory Bowel Disease", 
            "IBD"
        ], 
        "lastchanged_date": "December 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98105"
                }, 
                "name": "Seattle Children's Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Bacteriotherapy in Pediatric Inflammatory Bowel Disease", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary outcome measure is based on estimating the responder rate. This is defined as the proportion of patients with response to therapy by a drop of 10 or more points in PUCAI/PCDAI scoring.", 
            "measure": "Response to Stool Transplantation", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01757964"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seattle Children's Hospital", 
            "investigator_full_name": "David Suskind", 
            "investigator_title": "Associate Professor of Pediatrics", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Seattle Children's Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Seattle Children's Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "David Suskind", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}